These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3030098)

  • 1. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
    Jacobs TP; Gordon AC; Silverberg SJ; Shane E; Reich L; Clemens TL; Gundberg CM
    Am J Med; 1987 Feb; 82(2A):42-50. PubMed ID: 3030098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etidronate disodium in the management of malignancy-related hypercalcemia.
    Hasling C; Charles P; Mosekilde L
    Am J Med; 1987 Feb; 82(2A):51-4. PubMed ID: 3103436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
    Meunier PJ; Chapuy MC; Delmas P; Charhon S; Edouard C; Arlot M
    Am J Med; 1987 Feb; 82(2A):71-8. PubMed ID: 3103438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
    Kanis JA; Urwin GH; Gray RE; Beneton MN; McCloskey EV; Hamdy NA; Murray SA
    Am J Med; 1987 Feb; 82(2A):55-70. PubMed ID: 3103437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
    Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
    Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of hypercalcemia of malignancy.
    Singer FR; Fernandez M
    Am J Med; 1987 Feb; 82(2A):34-41. PubMed ID: 3826096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous etidronate in the management of malignant hypercalcemia.
    Ryzen E; Martodam RR; Troxell M; Benson A; Paterson A; Shepard K; Hicks R
    Arch Intern Med; 1985 Mar; 145(3):449-52. PubMed ID: 3919667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
    Singer FR; Ritch PS; Lad TE; Ringenberg QS; Schiller JH; Recker RR; Ryzen E
    Arch Intern Med; 1991 Mar; 151(3):471-6. PubMed ID: 1900410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
    Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etidronate disodium: a new therapy for hypercalcemia of malignancy. Proceedings of a symposium.
    Am J Med; 1987 Feb; 82(2A):1-78. PubMed ID: 3103434
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
    Ringenberg QS; Ritch PS
    Clin Ther; 1987; 9(3):318-25. PubMed ID: 3111705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
    Hasling C; Charles P; Mosekilde L
    Eur J Clin Invest; 1986 Oct; 16(5):433-7. PubMed ID: 3100312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
    Singer FR
    Semin Oncol; 1990 Apr; 17(2 Suppl 5):34-9. PubMed ID: 2110387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
    Flores JF; Singer FR; Rude RK
    Miner Electrolyte Metab; 1991; 17(6):390-5. PubMed ID: 1823390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.
    Warrell RP; Murphy WK; Schulman P; O'Dwyer PJ; Heller G
    J Clin Oncol; 1991 Aug; 9(8):1467-75. PubMed ID: 1906532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
    Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R
    J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate.
    Meythaler JM; Korkor AB; Nanda T; Kumar NA; Fallon M
    Arch Intern Med; 1986 Aug; 146(8):1567-71. PubMed ID: 3089187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ketoconazole reduces elevated serum levels of 1,25-dihydroxyvitamin D in hypercalcemic sarcoidosis.
    Glass AR; Cerletty JM; Elliott W; Lemann J; Gray RW; Eil C
    J Endocrinol Invest; 1990 May; 13(5):407-13. PubMed ID: 2166103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sodium etidronate (EHDP) and osteoporosis].
    Nuti R; Righi G; Turchetti V; Vattimo A
    Clin Ter; 1981 Oct; 99(1):33-42. PubMed ID: 6171376
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypercalcemia and abnormal 1,25-dihydroxyvitamin D concentrations in leprosy.
    Ryzen E; Rea TH; Singer FR
    Am J Med; 1988 Feb; 84(2):325-9. PubMed ID: 2841852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.